| TF Name |
Cell-line |
Condition/Source |
Collections |
Species |
Identifiers |
JASPAR ID |
| RBPJ |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
Treatment: agent VEGF, timepoint 1 Passage: P3-6 |
Permissive
|
Homo sapiens |
GSE109625
...
|
MA1116.1
|
| RBPJ |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
Treatment: agent VEGF, timepoint 4 Passage: P3-6 |
Permissive
|
Homo sapiens |
GSE109625
...
|
MA1116.1
|
| RBPJ |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
Treatment: agent VEGF, timepoint 12 Passage: P3-6 |
Permissive
|
Homo sapiens |
GSE109625
...
|
MA1116.1
|
| RBPJ |
HUVEC-C (HUVEC, umbilical vein endothelial cells) |
Treatment: Superconfluent, untreated Passage: 4 |
Permissive
|
Homo sapiens |
GSE87552
...
|
MA1116.1
|
| RBPJ |
REC-1 (Mantle cell lymphoma) |
Treatment: untreated |
Permissive
Robust
|
Homo sapiens |
GSE97541
...
|
MA1116.1
|
| RBPJ |
SP-49 (Mantle cell lymphoma) |
Treatment: untreated |
Permissive
Robust
|
Homo sapiens |
GSE97541
...
|
MA1116.1
|
| RBPJ |
REC-1 (Mantle cell lymphoma) |
Treatment: GSI-mock-washout |
Permissive
|
Homo sapiens |
GSE97541
...
|
MA1116.1
|
| RBPJ |
REC-1 (Mantle cell lymphoma) |
Treatment: GSI-washout |
Permissive
|
Homo sapiens |
GSE97541
...
|
MA1116.1
|
| RBPJ |
LAL-B (All-B patient-derived cell line) |
Treatment: chronic 1 uM dasatinib; |
Permissive
|
Homo sapiens |
GSE74557
...
|
MA1116.1
|
| RBPJ |
LAL-B (All-B patient-derived cell line) |
Treatment: 12 day 1 uM dasatinib; |
Permissive
|
Homo sapiens |
GSE74557
...
|
MA1116.1
|
Showing 10 records in page 473
from 658 pages